Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and
restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing
Escherichia coli and Klebsiella pneumoniae in hematology and oncology units
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Penicillanic Acid Piperacillin Piperacillin, Tazobactam Drug Combination Tazobactam